drugset / Trial / NCT03210909

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

NCT03210909

Phase 1 Completed 5 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

An intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986231

Timeline

Start
2017-06-22
Primary completion
2017-07-20
Completion
2017-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject cimlanod Other / unclassified Intravenous

Indications